NASDAQ$RPTX
Repare Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Repare Therapeutics reported financial results for Q4 2024, highlighted by portfolio re-prioritization and workforce reduction to extend cash runway into late 2027.
Repare Therapeutics announced a restructuring to focus on Phase 1 clinical programs RP-1664 and RP-3467, reducing its workforce by approximately 75%. The company's cash runway extends into late 2027 with $152.8 million in cash and cash equivalents. Initial clinical readouts from the POLAR trial are expected in Q3 2025, and from the LIONS trial in Q4 2025.
- Initiated Phase 1 clinical trial of RP-3467 (POLAR) in Q4 2024, dosing patients alone and in combination with olaparib.
- Topline safety, tolerability, and early efficacy data from the POLAR trial expected in Q3 2025.
- Initial topline safety, tolerability, and early efficacy data from the LIONS trial expected in Q4 2025.
- Company is reducing its workforce by approximately 75% to extend its cash runway into late-2027.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$0
Forward guidance
Repare Therapeutics is focused on advancing its Phase 1 clinical programs, RP-1664 and RP-3467, with clinical trial readouts expected in 2025. The company is also exploring partnerships across its portfolio, including for Lunre+Camo.
Tailwinds
- Initial clinical readout from Phase 1 RP-3467 (Polq ATPase/helicase inhibitor) POLAR trial expected in Q3 2025
- Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025
- Cash and cash equivalents and marketable securities provides runway to late-2027
- Evaluating lunresertib in combination with Debio 0123, a highly selective brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors
- Enrollment completion of MYTHIC trial evaluating lunresertib in combination with DEBIO 0123 (WEE1 inhibitor) in Q2 2025.
Headwinds
- Company reducing its workforce by approximately 75%
- Revenue from collaboration agreements was nil for the three-month period ended December 31, 2024
- Intends to seek partnering opportunities for Lunre+Camo program as a condition to further advancement of the program into pivotal development
- Will not continue to develop lunresertib or camonsertib in other studies unless a partner is found
- Restructuring expenses incurred
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2024
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro